Investors
OMX Stockholm
( %)
HNSA SEK
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Calendar
Upcoming events
11Nov
Interim Report for January-September 2026
Webcast at 14:00 CET / 8:00 AM EST: Hansa Biopharma Interim Report for January-September 2026
Live Q&A session: Register for Q&A
Press releases
Our latest press releases
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
